Get these analyses to your inbox — https://axial.substack.com/
In series with surveying AbCellera, Distributed Bio is an equally great business. Given its mission and technology, Distributed is one of the most important life sciences companies right now. Axial seeks to partner with companies like this that are centered around great inventors and frugalness. Although the revenue for Distributed is a little harder to pin down (likely in the same range of AbCellera), the amazing part of Distributed is that they did not raise venture capital. The founders bootstrapped the company out of their apartment and created an incredible company. Not only is Distributed impacting the lives of patients with a wide set of medicines, the company has the strongest technical moat in the antibody discovery field.
Distributed was founded by three individuals — Giles Days, Jacob Glanville, PhD (publishing machine), and Chris Smith. Whereas AbCellera was premised on a microfluidic technology, Distributed was formed around a computational engine. With a market measured in $100Bs and high clinical demand, the industry can support multiple large businesses. In particular, antibody discovery has 4 main features (market incentive, generic competition, clinical productivity, and new technologies) to enable unique transactions. Distributed not only is able to license out antibodies similar to…
